Five days after arriving in London from Jos a young Nigerian woman developed a severe and prolonged illness that proved to be Lassa fever. Virus was not detected in urine during the first three weeks but then appeared and reached a peak during the sixth week, with continuing excretion for 67 days after the onset of illness.
enlargement of lymph nodes. She had haematuria and proteinuria on chemical testing. White blood cell count was 16 2 x 109/l with a differential count of 6800 polymorphonuclear cells, 1600 lymphocytes, 900 monocytes, and 700/ abnormal mononuclear cells. Blood urea concentration was 12 6 mmol/l (76 mg/100 ml), plasma sodium 131 mmol(mEq)/1, and potassium 4 0 mmol(mEq)/l. The course of the illness strongly suggested Lassa fever, but the possibility of septicaemia could not be ruled out in view of the polymorphonuclear leucocytosis. Specimens were taken for virological and bacteriological studies and treatment started with chloramphenicol and one unit of Lassa fever convalescent serum. Supportive treatment was given with vitamin K, metoclopramide, and continuous intravenous infusion of an electrolyte and glucose solution.
The fever continued, but there was no further deterioration in her general condition. Blood pressure and blood urea concentration returned to normal after three days. The leucocytosis persisted and reached a peak of 26 x 109/l on 11 January. The erythrocyte sedimentation rate was surprisingly low at 25 mm in the first hour. Though haematuria continued for nearly three weeks, the only other evidence of bleeding was a small amount of blood-streaked sputum during the second week of illness.
The diagnosis was confirmed on 13 January by the presence of Lassa virus in blood cultures though not in urine. Chloramphenicol was stopped and a second unit of Lassa convalescent serum given on 16 January. She remained gravely ill, and her temperature did not return to normal until 29 January, 32 days after the onset of fever. Outstanding features of the illness were her extreme lassitude and complete loss of appetite, which did not improve until the last week of January. She remained unwell for a further month and lost a considerable amount of hair during convalescence.
Virus had cleared from her blood by 28 January but persisted in her urine until 8 March. At this point she was removed from the Trexler isolator and transferred to safe accommodation pending final clearance of urine. She was finally discharged from hospital on 27 March after her urine had been reported free from virus on four consecutive occasions.
Virological investigations
Lassa virus was isolated in Vero cell cultures from a blood sample taken on 8 January, which was estimated to be 12 days after the onset of the illness. Examination of the tissue culture isolate by electron microscope revealed typical arenavirus particles. The diagnosis was confirmed by indirect immunofluorescence assay using standard positive anti-Lassa sera. Virus isolations and serological studies were made on specimens of blood, urine, and throat washings collected during the acute and convalescent phases of the illness. The highest level of virus in the blood (105.2 median tissue culture infective dose/ml) was found in the sample taken on 8 January ( figure) ; the level then declined, and the virus was undetectable by day 32 (28 January).
No virus was isolated from urine samples collected before day 22 (18 January). Thereafter it was evident until day 67. The peak level of virus (104.0 median tissue culture infective dose/ml) was found in the urine on day 36, but levels ranging from 102.0 to 104.0 median tissue culture infective dose/ml were evident from days 22 to 53. The level fell gradually, and the virus was undetectable by day 71.
Throat washings taken throughout the patient's isolation did not yield any virus.
Circulating antibody levels were determined by immunofluorescence. Anti-Lassa antibody was present at a titre of 1/64 on day 22, and peak titres of 1/24 000 and 1/32 000 were reached on days 40 and 55: this level was sustained throughout the remainder of the illness. Circulating anti-Lassa antibody of 1/16 to 1/32 was detectable only between days 19 and 24.
Immunofluorescence titres of convalescent sera given on 9 January and 16 January were 1/1024 and 1/2048 respectively. The value of convalescent serum in the treatment of Lassa fever has not been established. Some have found it to be beneficial,3 while others have been less impressed.4 In our patient there did not appear to be any harmful effects, and in particular no deterioration in renal function occurred. Although her temperature fell briefly after the first infusion of serum, there was no obvious change in her general condition and no apparent effect on the concentration of virus in her blood. Moreover, virus did not appear in her urine until after the first infusion and persisted after the second.
Restoration of water and electrolytes improved renal function, and infusion of glucose appeared clinically to arrest deterioration in liver function. Apart from giving regular injections of vitamin K we made no attempt to restore clotting factors, but fortunately no serious haemorrhage occurred.
During the acute stage of the illness the presence of virus in blood severely restricted haematological and biochemical investigations to guide management. The striking polymorphonuclear leucocytosis is an unusual finding in an acute virus infection but could well be attributed to the extensive cellular damage. Abnormal mononuclear cells are common in some virus infections and are of uncertain importance. The kidneys in particular were affected in this patient, who showed an initial rise in blood urea concentration followed by prolonged haematuria and proteinuria. The lack of evidence of disseminated intravascular coagulation' suggests that the disturbance of clotting and tendency to bleed were probably related to impaired liver function and vascular endothelial damage. She 
